SAB Biotherapeutics (SABSW) Net Income towards Common Stockholders (2021 - 2025)
Historic Net Income towards Common Stockholders for SAB Biotherapeutics (SABSW) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.
- SAB Biotherapeutics' Net Income towards Common Stockholders fell 1659.63% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year increase of 1491.11%. This contributed to the annual value of -$34.1 million for FY2024, which is 1916.98% up from last year.
- Latest data reveals that SAB Biotherapeutics reported Net Income towards Common Stockholders of -$12.1 million as of Q3 2025, which was down 1659.63% from -$10.1 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Net Income towards Common Stockholders registered a high of $1.4 million during Q1 2021, and its lowest value of -$22.9 million during Q4 2023.
- Its 5-year average for Net Income towards Common Stockholders is -$7.3 million, with a median of -$7.1 million in 2022.
- Per our database at Business Quant, SAB Biotherapeutics' Net Income towards Common Stockholders plummeted by 84592.72% in 2023 and then soared by 5014.74% in 2024.
- SAB Biotherapeutics' Net Income towards Common Stockholders (Quarter) stood at -$11.6 million in 2021, then surged by 31.83% to -$7.9 million in 2022, then plummeted by 190.26% to -$22.9 million in 2023, then soared by 50.15% to -$11.4 million in 2024, then decreased by 5.9% to -$12.1 million in 2025.
- Its last three reported values are -$12.1 million in Q3 2025, -$10.1 million for Q2 2025, and -$5.2 million during Q1 2025.